Filing Flows › Pacific Biosciences of California (PACB) › Q2 2025
Pacific Biosciences of California (PACB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Pacific Biosciences of California (PACB) reported revenue of $39.8M for the second quarter 2025 (Q2 2025), +10% from a year earlier and +7% from the quarter before. Operating margin was -112.8%, net loss $41.9M (105.4% of revenue).
Pacific Biosciences of California, Q2 2025: revenue $39.8M (+10% year over year), operating margin -112.8%, net loss $41.9M, operating cash flow −$29.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $39.8M | +7% | +10% |
| Operating profit | −$44.9M | — | — |
| Net earnings | −$41.9M | — | — |
| Operating cash flow | −$29.4M | — | — |
What changed
Revenue was $39.8M in Q2 2025, up 10% year over year and up 7% from the previous quarter. Consumable revenue was the largest line at 48% of revenue. Service and other revenue added $2.4M year over year (up 57%), 64% of the total change. Instrument revenue declined 4%.
Gross margin was 36.9%, up 20.4 points from a year earlier. Operating costs exceeded revenue by $44.9M, an operating margin of -112.8%. Operating expenses fell 67% while revenue rose 10%. The quarter ended with a net loss of $41.9M, narrower than the previous quarter's $426.1M loss.
Operating cash flow was −$29.4M. Non-cash charges added back $3.7M of depreciation and amortization and $11.9M of share-based compensation. Working capital and other items used $3.0M. Capital expenditures of $550K exceeded it, leaving free cash flow of −$29.9M.
Questions
What was Pacific Biosciences of California's revenue in the second quarter 2025?
Pacific Biosciences of California (PACB) reported revenue of $39.8M for the second quarter 2025 (Q2 2025), +10% from a year earlier and +7% from the quarter before.
Was Pacific Biosciences of California profitable in the second quarter 2025?
Operating loss was $44.9M (-112.8% of revenue) and net loss $41.9M.
Source: Pacific Biosciences of California 10-Q on SEC EDGAR.